Daratumumab combo for rare kidney diseases
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests a combination of three drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with rare kidney diseases caused by abnormal plasma cells. It aims to see if this treatment can help control the disease and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these rare kidney conditions: PGNMIDs, LCPT, TMA, or CGGN.
- The abnormal plasma cells must be found in your bone marrow.
- You should be able to take care of yourself (ECOG score 0, 1, or 2).
- Your blood counts need to be high enough: neutrophils at least 1.0, hemoglobin at least 70, platelets at least 50.
- Your liver function tests (bilirubin, AST, ALT) must be within a safe range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
This Phase 2 study tests daratumumab (an immune-targeting medicine) in people with PGNMID, a kidney disease where abnormal immune proteins build up in the kidney filters. It aims to reduce harmful protein in the urine and improve kidney health.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
Hear when a new Monoclonal Gammopathy of Renal Significance (MGRS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.